Inhibition of aldose reductase ameliorates diet‑induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α

Chen,Tong; Shi,Duanyu; Chen,Jinfeng; Yang,Yanxue; Qiu,Mengguang; Wang,Wei; Qiu,Longxin

doi:10.3892/mmr.2014.2713

Inhibition of aldose reductase ameliorates diet‑induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α

Authors:
- Tong Chen
- Duanyu Shi
- Jinfeng Chen
- Yanxue Yang
- Mengguang Qiu
- Wei Wang
- Longxin Qiu
View Affiliations

Affiliations: Department of Biology, School of Life Sciences, Longyan University, Longyan, Fujian 364000, P.R. China
Published online on: October 21, 2014 https://doi.org/10.3892/mmr.2014.2713
Pages: 303-308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aldose reductase (AR) is involved in the pathogenesis of nonalcoholic steatohepatitis. This study aimed to determine the mechanism by which AR affects the development of murine diet‑induced nonalcoholic steatohepatitis. Steatohepatitis was induced in C57BL/6 mice by administration of a methionine‑choline‑deficient (MCD) diet, a commonly used nutrition‑induced model of steatohepatitis. Hematoxylin and eosin staining was used for histological analyses. Western blot analyses were used to determine protein expression levels and quantitative polymerase chain reaction was used to analyze mRNA expression levels. The results showed that the AR protein expression level was significantly higher in C57BL/6 mice fed the MCD diet than in mice fed the control diet. Diet‑induced hepatic steatosis and necroinflammation were attenuated in the MCD diet‑fed mice treated with the AR inhibitor, zopolrestat. The ameliorating effect of AR inhibition on steatohepatitis was associated with decreased levels of serum alanine aminotransferase and hepatic lipoperoxides, reduced expression of phosphorylated peroxisome proliferator‑activated receptor (PPAR)α and increased mRNA expression of acyl coenzyme A oxidase. These data indicated that induction of hepatic AR expression in mice with steatohepatitis resulted in the phosphorylation of PPARα and suppression of PPARα activity. Inhibition of AR decreased lipid accumulation and inflammation in the liver, at least in part through the modulation of PPARα phosphorylation and PPARα transcriptional activity.

View Figures

View References

1	Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:434–438. 1980.PubMed/NCBI
2	Day CP and James OF: Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 114:842–845. 1998.
3	Kota BP, Huang TH and Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res. 51:85–94. 2005. View Article : Google Scholar : PubMed/NCBI
4	Abdelmegeed MA, Yoo SH, Henderson LE, et al: PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr. 141:603–610. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ip E, Farrell G, Hall P, et al: Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 39:1286–1296. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ip E, Farrell GC, Robertson G, et al: Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 38:123–132. 2003. View Article : Google Scholar : PubMed/NCBI
7	Clements RS Jr: The polyol pathway. A historical review. Drugs. 32(Suppl 2): 3–5. 1986. View Article : Google Scholar
8	Brown KE, Broadhurst KA, Mathahs MM, et al: Immunodetection of aldose reductase in normal and diseased human liver. Histol Histopathol. 20:429–436. 2005.PubMed/NCBI
9	O’Connor T, Ireland LS, Harrison DJ and Hayes JD: Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J. 343:487–504. 1999.PubMed/NCBI
10	Takahashi M, Hoshi A, Fujii J, et al: Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn J Cancer Res. 87:337–341. 1996. View Article : Google Scholar : PubMed/NCBI
11	Qiu L, Lin J, Xu F, et al: Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res. 2012:7897302012.PubMed/NCBI
12	Qiu L, Wu X, Chau JF, et al: Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. J Biol Chem. 283:17175–17183. 2008. View Article : Google Scholar
13	Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 21:3–16. 2001. View Article : Google Scholar : PubMed/NCBI
14	Sahai A, Malladi P, Pan X, et al: Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol. 287:G1035–G1043. 2004. View Article : Google Scholar : PubMed/NCBI
15	Qiu L, Lin J, Ying M, et al: Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis. PLoS One. 8:e735912013. View Article : Google Scholar : PubMed/NCBI
16	Lefebvre P, Chinetti G, Fruchart JC and Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 116:571–580. 2006. View Article : Google Scholar : PubMed/NCBI
17	Djouadi F, Weinheimer CJ, Saffitz JE, et al: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest. 102:1083–1091. 1998. View Article : Google Scholar
18	Burns KA and Vanden Heuvel JP: Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta. 1771:952–960. 2007. View Article : Google Scholar : PubMed/NCBI
19	Gelman L, Michalik L, Desvergne B and Wahli W: Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr Opin Cell Biol. 17:216–222. 2005. View Article : Google Scholar : PubMed/NCBI
20	Barger PM, Brandt JM, Leone TC, et al: Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 105:1723–1730. 2000. View Article : Google Scholar : PubMed/NCBI
21	Tamasi V, Miller KK, Ripp SL, et al: Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol. 73:968–976. 2008. View Article : Google Scholar
22	Koek GH, Liedorp PR and Bast A: The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 412:1297–1305. 2011. View Article : Google Scholar : PubMed/NCBI
23	Voican CS and Perlemuter G: Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol. 54:388–391. 2011. View Article : Google Scholar : PubMed/NCBI
24	Esterbauer H, Schaur RJ and Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 11:81–128. 1991. View Article : Google Scholar : PubMed/NCBI
25	Vander Jagt DL, Kolb NS, Vander Jagt TJ, et al: Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta. 1249:117–126. 1995.PubMed/NCBI
26	Spycher S, Tabataba-Vakili S, O’Donnell VB, et al: 4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem Biophys Res Commun. 226:512–516. 1996. View Article : Google Scholar : PubMed/NCBI
27	Rittner HL, Hafner V, Klimiuk PA, et al: Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest. 103:1007–1013. 1999. View Article : Google Scholar : PubMed/NCBI
28	Ruef J, Liu SQ, Bode C, et al: Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol. 20:1745–1752. 2000. View Article : Google Scholar : PubMed/NCBI
29	Tracey WR, Magee WP, Ellery CA, et al: Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 279:H1447–H1452. 2000.PubMed/NCBI
30	Yadav UC, Ramana KV, Aguilera-Aguirre L, et al: Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One. 4:e65352009. View Article : Google Scholar : PubMed/NCBI
31	Yadav UC, Srivastava SK and Ramana KV: Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 48:4634–4642. 2007. View Article : Google Scholar : PubMed/NCBI